Document is current

Article History

Received: 25 November 2024

Revised: 24 January 2025

Accepted: 27 January 2025

First Online: 20 February 2025

Declarations

:

: AGOL is the Past President of the Pacific Dermatology Association and serves as an associate editor for Dermatology (Karger) and honorary editorial member for the American Journal of Clinical Dermatology. In addition, he is a consultant for Genentech, Guidepoint, InflaRx GmbH, Corvus Pharmaceuticals, Castle Biosciences, Clarivate, TFS HealthScience, Otsuka, Leo Pharma, and an advisor to Bristol Meyer Squibb, Boehringer Ingelheim, Janssen and Sanofi. He has also received research grants from Lilly, Janssen, Incyte and Pfizer and is supported by NIH NIAMS R01 AR083110. FB has been a consultant adviser and clinical study investigator for Eli Lilly, Abbvie, Novartis, Leo Pharma, Sandoz, Bristol Myers, Abiogen-Pharma, Celgene and Janssen. DOC worked as a consultant for UCB, Bausche, Novartis, Abbvie and Sanofi. DMC is an employee of Genentech, a member of the Roche Group. SS has served as an advisor to Boehringer Ingelheim and received consulting fees from OnQuality Pharmaceutical. AM receives consulting fees and/or honoraria from Pfizer, hims and hers, Sun Pharmaceuticals, Digital Diagnostics, Concert, Lilly, Abbvie, Equillium, ASLAN, ACOM, and Boehringer Ingelheim. He also owns equity in hims, Fig. 1, Acom, and Seebe. He receives licensing fees and royalties from Pfizer, Concert, and Lilly. He serves on the medical advisory board for hims, Fig. 1, and Digital Diagnostics. He oversees clinical trials for Lilly and Concert, and he is an associate editor at JAMA Dermatology. BHK is an investigator for AnaptysBio Inc, Biogen, InflaRx, Onquality Pharmaceuticals, and Eli Lilly Co and is funded by the Dermatology Foundation. MI serves as a consultant medical expert at InflaRx GmbH. All other authors have no conflicts of interest to disclose.